Results 31 to 40 of about 8,196 (186)

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, EarlyView.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

Specialist Palliative Care and the Use of Healthcare Services Among Patients With Multiple Myeloma: A Nationwide Cohort Study

European Journal of Haematology, EarlyView.
ABSTRACT Objectives To investigate the access to specialist palliative care (SPC) and its impact on healthcare utilization at the end of life in patients with multiple myeloma (MM). Methods This retrospective cohort study examined all Finnish patients who died of MM in 2019. Data were collected from national health databases.
Annasofia Holopainen, Hanna‐Riikka Lehto, Taru Kuittinen, Mikko Nuutinen, Kristiina Tyynelä‐Korhonen, Annamarja Lamminmäki, Tiina Saarto, Timo Carpén   +7 more
wiley   +1 more source

Primary extramedullary plasmacytoma of the sigmoid colon with perforation: a case report

Surgical Case Reports, 2018
Background Extramedullary plasmacytomas account for 4% of all plasma cell tumors and occur mainly in the upper respiratory tract; gastrointestinal system involvement is rare. Extramedullary plasmacytoma of the colon with perforation has not been reported.
Fumimasa Kitamura, Koichi Doi, Hiroyuki Ishiodori, Tetsufumi Ohchi, Hideo Baba   +4 more
doaj   +1 more source

Hematological entities with plasmacytic differentiation: a case report 

Journal of Medical Case Reports, 2023
Introduction Plasmacytoma, a localized tumor of monoclonal plasma cells without any clinical, radiological or physical evidence of plasma cell neoplasm (PCN), is a rare entity that accounts for 1% of PCN.
Arati Inamdar, Siddharth Bhattacharyya
doaj   +1 more source

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease.
Iuliana Vaxman, Itai Zamir, Inbar Cohen, Gil Fridberg, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Ronit Shmuel, Natan Melamed, Shai Levy, Irit Avivi, Pia Raanani, Angela Dispenzieri, Morie A. Gertz, Yael C. Cohen   +15 more
wiley   +1 more source

Extramedullary plasmacytoma of the uterine cervix arising in an asymptomatic 46-year-old female

Gynecologic Oncology Reports, 2022
An extramedullary plasmacytoma is a rare type of plasma cell tumour that can be found in soft tissues throughout the body. The most common location for an extramedullary plasmacytoma is in the head and neck region.
Nicole Wiebe, Nikhil Sangle, Jacob McGee
doaj   +1 more source

Prognostic Effect of Sarcopenia and Nutritional Factors on Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Exploratory Study

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Multiple myeloma (MM) is a hematological malignancy associated with poor prognosis. Prognostic prediction based on patient fitness may facilitate the optimization of therapeutic strategies. This study aimed to explore the prognostic significance of sarcopenia, the prognostic nutritional index (PNI) and the controlling nutritional ...
Xuxing Shen, Jiapei Yu, Xin Cheng, Ye Yao, Yuanyuan Jin, Qinglin Shi, Lijuan Chen   +6 more
wiley   +1 more source

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated the feasibility of discontinuing antimyeloma therapy in patients with MRD negativity.
Kota Sato, Kenshi Suzuki, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Moe Yogo, Tomomi Takei, Mizuki Ogura, Yu Abe, Taku Kikuchi, Nobuhiro Tsukada, Tadao Ishida   +11 more
wiley   +1 more source

Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings

Radiology Case Reports, 2019
Extramedullary plasmacytoma of the breast (EPB), a manifestation of multiple myeloma (MM), is very rare. It is important to recognize the imaging findings of EPB because it may be the first manifestation of relapsed MM.
Misugi Urano, MD, Fatmaelzahraa Abdelfattah Denewar, MD, Ryo Okabe, MD, Hirokazu Komatsu, MD, Yumi Wanifuchi-Endo, MD, Tatsuya Toyama, MD, Yuta Shibamoto, MD   +6 more
doaj   +1 more source

Extramedullary Disease—Achilles Heel in Myeloma?

American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.
ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar, Joshua Richter, Saad Z. Usmani, Yael C. Cohen, Jing Christine Ye, María‐Victoria Mateos, Vania Hungria, Elena Zamagni   +7 more
wiley   +1 more source